Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biopharmaceutical firm ChemoCentryx has started patient enrollment in a Phase Ib clinical trial with its clinical compound, CCX872, to treat non-resectable pancreatic cancer.
Subscribe to our email newsletter
The company’s second clinical compound, CCX872 is an orally administered inhibitor of the chemokine receptor known as CCR2.
Around 54 patients with non-resectable pancreatic cancer will be included in the trial, which is designed to evaluate the safety and efficacy of orally administered CCX872 plus FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin).
Initially, patients will be treated for 12 weeks and those who achieve at least stable disease, as measured by Response Evaluation Criteria In Solid Tumors, or RECIST 1.1, will be eligible to continue treatment unless disease progression occurs.
The trial’s primary efficacy measurement will be progression-free survival (PFS).
ChemoCentryx president and chief executive officer Thomas Schall said: "Despite recent advancements in treating pancreatic cancer, tumors undermine inflammatory and effector immune responses through suppressor cells thought to be controlled by the chemokine receptor known as CCR2.
"Our belief is that by blocking CCR2 with the specific receptor inhibitor CCX872, we can eliminate the CCR2-guided immune suppressor cells in the tumor microenvironment and consequently promote a more effective anti-tumor response."
The company intends to report initial data from the open-label, multi-center trial by the end of 2015.